TLPHHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Talphera, Inc. hold a median 12-month price target of $3 — +185.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 7 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Talphera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TLPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +185.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 June 2026 | HC Wainwright & Co. | Assumes | Buy | $3.00 |
| 30 Apr 2026 | WestPark Capital | Initiates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | Maxim Group | Initiates | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Dec 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Oct 2023 | Alliance Global Partners | Initiates | Buy | — |
| 25 Sept 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Aug 2023 | HC Wainwright & Co. | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLPH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Talphera, Inc. returned −16.7% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 1% of US stocks
Cheaper than 25% of US stocks
Cheaper than 77% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 10% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Talphera, Inc. has a market value of $57.6M and an enterprise value of $47.0M.
Revenue in the twelve months to 30 June 2026: $1K.
Net income over the same four quarters: −$15.1M, a −1507600.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.27.
Free cash flow in the twelve months to 30 June 2026: −$12.3M.
Trailing P/E: −3.1×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Talphera, Inc. employs 12 people — $83.3 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Talphera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Talphera (TLPH) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could push the stock higher in the near term.
Why it matters — A Zacks upgrade to a Buy rating signals improved analyst sentiment about Talphera's near-term earnings outlook, which may be of interest to those following the stock.
Talphera, Inc. announced that company management will be presenting at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on September 3, 2026.
Why it matters — A company presentation at a major investor conference gives Talphera watchers an opportunity to hear management's latest updates on the company's development and commercialization activities.
Talphera, Inc. (TLPH) held its Q2 2026 earnings call, and the transcript of the call was published on Seeking Alpha. The headline indicates the earnings call transcript is now available for the period.
Why it matters — A TLPH watcher would care because the earnings call transcript provides a detailed account of the company's Q2 2026 performance and management commentary directly from the call.
Talphera, Inc. announced its second-quarter 2026 financial results and a corporate update on nafamostat. The NEPHRO CRRT clinical study is 75% enrolled and expected to complete this year, updated draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, and market research now estimates 200,000 annual U.S. CRRT procedures. Cash and investments were $17.1 million at June 30, 2026, and a conference call is scheduled for August 12, 2026.
Why it matters — Talphera watchers would care because the company provided progress on its lead nafamostat program, including enrollment nearing completion, a favorable KDIGO guideline change, and updated market sizing.
Talphera, Inc. announced it will report its second quarter 2026 financial results on Wednesday, August 12, 2026, hosting a conference call and webcast at 4:30 p.m. that day.
Why it matters — The scheduled earnings call gives TLPH watchers a date to hear the company's latest quarterly financial results and commentary.
The 4 Wall Street analysts covering Talphera, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Talphera, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Talphera, Inc. 40 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 7 Oct 2026, Talphera, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +185.7% from the last close, and Ticker Nerd's factor model ranks Talphera, Inc. 40 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Talphera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3.5 over the next 12 months.
Talphera, Inc. returned -16.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings.
The most recent item we track (Zacks Investment Research, 21 Sept 2026): "Talphera (TLPH) Upgraded to Buy: Here's What You Should Know". Talphera (TLPH) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could push the stock higher in the near term.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings. The company’s current portfolio centers on nafamostat product candidates and pre-filled syringe products designed for acute care environments, including hospital and procedural settings. Its lead program, Niyad, is a lyophilized formulation of nafamostat being studied as a regional anticoagulant for the extracorporeal circuit, while its broader pipeline includes pre-filled syringe products such as ephedrine and phenylephrine formulations. Talphera serves healthcare providers by targeting needs in high-acuity care where reliable, ready-to-use therapies can support treatment workflows. Headquartered in San Mateo, California, Talphera remains focused on specialty pharmaceuticals for medically supervised use.
CEO Mr. Vincent J. Angotti · 12 employees · United States · https://talphera.com
